Video

Charting the progress of BenevolentAI’s collaboration with AstraZeneca

In April 2019, we announced a collaboration with AstraZeneca to design and develop new treatments for disease beginning with chronic kidney disease and idiopathic pulmonary fibrosis.

By combining our AI and machine learning capabilities with AstraZeneca’s disease area expertise and large, diverse datasets, we hope to improve our understanding of complex disease biology and more quickly identify new potential drug targets.

Our biologists, chemists, engineers, informaticians and data scientists, are working together with our peers at AstraZeneca  to provide new opportunities in understanding and targeting these diseases. In this video, scientists from the centre of the project chart the progress of the collaboration and share their reflections on changing the way we do drug discovery, to enable more efficient and data-driven development  of new medicines.

In our opinion,  partnerships aren’t forged on paper. You can’t write a partnership into being. It has to be based on a professional respect, shared ambition and a common set of values. For us this is the fusion of human expertise with technological innovation. That collision of capabilities is what will help us work  together to  help more people live longer, healthier lives.


More Posts

You Might Also Like

Events
BenevolentAI at ICML 2020
We are pleased to announce that BenevolentAI is sponsoring the virtual ICML 2020 conference from the 12th - 18th of July. You can find our team on the EXPO workshop and Women in ML stage - we hope to meet you there.
Jul 12, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Events
New tech brings new hope in our new normal | A Keynote from Joanna Shields at WeAreTechWomen
In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.
Jun 26, 2020
Events
Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.
Our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease
Jun 9, 2020
Video
How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020